Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1981 twice daily for 61/2 days · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1981 100 mg twice daily for 6 ½ days |
| Name | Type | Description |
|---|---|---|
| AZD1981 100 mg twice daily for 61/2 days | DRUG | 100 mg tablets |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * A minimum of 6 months documented history of asthma * Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to Visit 1 (pre-entry) Exclusion Criteria: * Any clinically significant disea...
AZD1981 is an investigational small molecule being developed for the treatment of asthma. It is a respiratory therapeutic that has been studied in a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
AZD1981 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company has conducted clinical research on this investigational asthma treatment.
AZD1981 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a pharmacokinetic study in adolescents with asthma. The drug is investigational and has not been approved by regulatory authorities.
AZD1981 has been studied in one completed Phase 1 clinical trial, identified as NCT01196689. This trial, titled "Pharmacokinetics in Adolescents," enrolled 21 male participants aged 12 years and older with asthma in Sweden. The study was uncontrolled and not blinded.
AZD1981 is a small molecule therapeutic being developed for asthma. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not fully characterized in public data.